Skip to main content

Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Background:

Topical 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT) is increasingly used for superficial non-melanoma skin cancers and their precursors. Methods:

We report our 3-year experience of topical ALA-PDT, with a preliminary comparison of the effects of broadband and laser light sources. Results:

We performed 688 treatments on 483 lesions in 207 patients. Complete clearance was achieved in 222/239 lesions of Bowen's disease (BD), superfi-cial basal cell carcinoma (sBCC) and actinic keratosis (AK) (93%) – 117/129 BD (91%), 84/87 sBCC (97%) and 21/23 AK (91%), with a median follow up of 48 weeks. Broadband and laser light sources were of similar efficacy. Recurrences have occurred in 10.3% BD, 4.8% sBCC and 4.8% AK. Adverse effects from PDT were uncommon but included pig-mentary change (2%) and minor scarring (2%). How-ever, severe pain was experienced in 16–21% of treatments using the high-output broadband and laser sources, but in only 2% with the low-output xenon arc source. Conclusion:

Topical ALA-PDT is effective for BD, sBCC and AK and has been an invaluable addition to our dermatology service. Efficacy is similar for broadband and laser light sources, although treatment at higher surface irradiance may be painful, and excellent cosmetic results can be achieved.

Keywords: 5-aminolaevulinic acid; Bowen's disease; actinic keratosis; photodynamic therapy; superficial basal cell carcinoma

Document Type: Research Article

DOI: http://dx.doi.org/10.1034/j.1600-0781.2003.00024.x

Publication date: June 1, 2003

mksg/ppp/2003/00000019/00000003/art00004
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more